Ultragenyx Pharmaceutical, Inc. (RARE)
15.22
+0.47
(+3.19%)
USD |
NASDAQ |
Oct 02, 16:00
15.33
+0.11
(+0.72%)
After-Hours: 20:00
Ultragenyx Pharmaceutical Gross Profit Margin (Quarterly) : 80.37% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 80.37% |
| March 31, 2026 | 72.06% |
| December 31, 2025 | 81.75% |
| September 30, 2025 | 77.12% |
| June 30, 2025 | 81.01% |
| March 31, 2025 | 72.97% |
| December 31, 2024 | 84.25% |
| September 30, 2024 | 78.65% |
| June 30, 2024 | 79.50% |
| March 31, 2024 | 75.76% |
| December 31, 2023 | 90.54% |
| September 30, 2023 | 88.79% |
| June 30, 2023 | 90.85% |
| March 31, 2023 | 83.29% |
| December 31, 2022 | 91.12% |
| September 30, 2022 | 86.08% |
| June 30, 2022 | 86.51% |
| March 31, 2022 | 88.13% |
| December 31, 2021 | 91.55% |
| September 30, 2021 | 90.95% |
| June 30, 2021 | 92.81% |
| Date | Value |
|---|---|
| March 31, 2021 | 91.39% |
| December 31, 2020 | 90.59% |
| September 30, 2020 | 93.32% |
| June 30, 2020 | 91.92% |
| March 31, 2020 | |
| December 31, 2019 | 79.56% |
| September 30, 2019 | 81.29% |
| June 30, 2019 | 88.11% |
| March 31, 2019 | 85.85% |
| December 31, 2018 | 78.78% |
| September 30, 2018 | 60.66% |
| June 30, 2018 | 51.38% |
| March 31, 2018 | 40.20% |
| December 31, 2017 | -4.18% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| AbbVie, Inc. | 74.71% |
| Biogen, Inc. | 61.37% |
| BioMarin Pharmaceutical, Inc. | 72.27% |
| Ionis Pharmaceuticals, Inc. | 96.13% |
| Regeneron Pharmaceuticals, Inc. | 83.68% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -44.50% |
| Return on Invested Capital | -58.78% |
| Profit Margin (Quarterly) | -42.99% |
| Operating Margin (Quarterly) | -35.05% |
| Return on Net Operating Assets | -88.37% |